Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in January

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 31st total of 2,680,000 shares. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is presently 11.8 days. Approximately 7.4% of the shares of the stock are sold short.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds have recently bought and sold shares of the business. Quest Partners LLC increased its holdings in shares of Astria Therapeutics by 180.8% in the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Astria Therapeutics in the 4th quarter valued at approximately $107,000. PDT Partners LLC acquired a new stake in shares of Astria Therapeutics during the 3rd quarter valued at $140,000. SG Americas Securities LLC acquired a new position in shares of Astria Therapeutics in the third quarter worth $155,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Astria Therapeutics during the second quarter worth $171,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on ATXS shares. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Stock Performance

ATXS traded up $0.03 during trading on Thursday, reaching $7.49. The company had a trading volume of 213,482 shares, compared to its average volume of 301,162. The firm’s 50-day simple moving average is $9.00 and its 200 day simple moving average is $10.49. The company has a market cap of $422.66 million, a price-to-earnings ratio of -3.58 and a beta of 0.70. Astria Therapeutics has a 12-month low of $7.16 and a 12-month high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.